The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Systemic VSV-IFNβ-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma.
 
Nabila Nora Bennani
Consulting or Advisory Role - Acrotech Biopharma (Inst); Affimed Therapeutics (Inst); Daiichi Sankyo (Inst); Kymera (Inst); Kyowa Kirin International (Inst); Secura Bio (Inst); Vividion Therapeutics (Inst)
Research Funding - Vyriad (Inst)
 
Joselle Cook
No Relationships to Disclose
 
Kah-Whye Peng
Employment - Vyriad
Research Funding - Vyriad
 
Susan Michelle Geyer
Research Funding - Brisol-Myers-Squibb (Inst); Celgene (Inst); Johnson & Johnson/Janssen (Inst)
 
Brenda F. Ginos
No Relationships to Disclose
 
Lianwen Zhang
No Relationships to Disclose
 
Sharina C. Macapagal
No Relationships to Disclose
 
Thomas E. Witzig
Honoraria - Curio Science; Curio Science (Inst)
Consulting or Advisory Role - Salarius Pharmaceuticals; Tornado Therapeutics
Research Funding - Acerta Pharma (Inst); Acrotech Biopharma (Inst); Celgene (Inst); Karyopharm Therapeutics (Inst); Kura Oncology (Inst)
Patents, Royalties, Other Intellectual Property - I am co-inventor on a patent application filed by Mayo Clinic and pending on the combination of CRM1 inhibitors with salicylates. Please note - simply filed - not even close to being granted. (Inst)
 
Javier Munoz
Honoraria - Curio Science; Kyowa Hakko Kirin; OncView; Physicans' Education Resource; Seagen; Targeted Oncology
Consulting or Advisory Role - ADC Therapeutics; Alexion Pharmaceuticals; Aurobindo; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Debiopharm Group; Epizyme; Fosun Kite; Genentech; Genmab; Gilead Sciences; Innovent Biologics; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; MEI Pharma; MorphoSys; Novartis; Pfizer; Pharmacyclics; Seagen; Secura Bio; SERVIER; TG Therapeutics; Zodiac Pharma
Speakers' Bureau - Abbvie/Genentech; Acrotech Biopharma; AstraZeneca; Bayer; BeiGene; BeiGene; Celgene; Gilead Sciences; Kite, a Gilead company; Kyowa Hakko Kirin; Pharmacyclics/Janssen; Seagen; Verastem
Research Funding - Celgene; Genentech/Abbvie; Incyte; Kite, a Gilead company; Millennium; Pharmacyclics/Janssen; Portola Pharmaceuticals; Seagen
 
Stephen M Broski
No Relationships to Disclose
 
Stephen J. Russell
Employment - Vyriad
Leadership - Vyriad
Stock and Other Ownership Interests - Vyriad
Patents, Royalties, Other Intellectual Property - Mayo Clinic/Vyriad
 
Martha Lacy
Research Funding - Vyriad (Inst)